Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Trading banner 1
Trading banner 2
Trading banner 3
Trading banner 4
Trading banner 5
Trading banner 6
Trading banner 7
Trading banner 8
Trading banner 9
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell AbbVie Inc (ABBV) – AbbVie Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

AbbVie (ABBV) trades at $204.98, down 0.57% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth to $61.16B in 2025, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed. Recent positive Phase 2 data for ELAHERE in ovarian cancer highlights pipeline progress. Cash flow from operations remains robust at $18.81B, but significant investing outflows for 2024 resulted in negative net cash flow.
The outlook is supported by a strong analyst consensus (68% Buy) and a $261.89 price target, implying ~28% upside. Key opportunities include the successful immunology portfolio transition and a recovering dividend. Primary risks are execution of the oncology pipeline, looming patent cliffs in the 2030s, and high valuation multiples (P/E 100.5, EV/EBITDA 48.2) that demand sustained growth.
Read full analysis

Key Stats

  • Market Cap
    $358.55B
  • Sector
    Health
  • 3M Drawdown
    -16.43%
  • Enterprise Value
    $420.78B
  • Dividend Yield
    3.41%
  • Trading Activity
    51% Buy | 49% Sell
  • Typical Hold Time
    90 days
$202.56
52W Low: $177.44
14 May 2025
52W High: $244.38
01 Oct 2025

AbbVie Inc (ABBV) is currently valued at a market capitalization of $358.55B, with an enterprise value of $420.78B. Over the past 52 weeks, AbbVie Inc has traded between a low of $177.44 and a high of $244.38, highlighting its annual price range. Over the past three months, AbbVie Inc has recorded a drawdown of -16.43%, reflecting recent price volatility. AbbVie Inc offers a dividend yield of 3.41%, with the most recent dividend of $1.73 paid on 15 Apr 26. On average, investors hold AbbVie Inc for approximately 90 days, indicating typical investor behavior on the platform.

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.


Technical Indicators
|
|
|
Overall Summary
Bearish (17)Neutral (8)Bullish (2)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $358.55B
  • Sector
    Health
  • 3M Drawdown
    -16.43%
  • Enterprise Value
    $420.78B
  • Dividend Yield
    3.41%
  • Trading Activity
    51% Buy | 49% Sell
  • Typical Hold Time
    90 days
$202.56
52W Low: $177.44
14 May 2025
52W High: $244.38
01 Oct 2025

AbbVie Inc (ABBV) is currently valued at a market capitalization of $358.55B, with an enterprise value of $420.78B. Over the past 52 weeks, AbbVie Inc has traded between a low of $177.44 and a high of $244.38, highlighting its annual price range. Over the past three months, AbbVie Inc has recorded a drawdown of -16.43%, reflecting recent price volatility. AbbVie Inc offers a dividend yield of 3.41%, with the most recent dividend of $1.73 paid on 15 Apr 26. On average, investors hold AbbVie Inc for approximately 90 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!